Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors

Next Previous
Trial Profile

A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NEST 1 (Primary)
  • Indications Glioma; Malignant melanoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Nested Therapeutics

Most Recent Events

  • 17 Sep 2024 Trial design published at the 49th European Society for Medical Oncology Congress.
  • 08 Apr 2024 According to a Nested Therapeutics media release, the company expects to initiate dosing imminently
  • 28 Mar 2024 According to a Nested Therapeutics media release, today U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for NST-628 f and company expects to initiate dosing in Phase 1 study of NST-628 in patients with advanced solid tumors in first half of 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top